<DOC>
	<DOCNO>NCT02056847</DOCNO>
	<brief_summary>Primary Objective : To evaluate different effect HbA1c routine lipid lower therapy ( Livalo 2mg ) intensive lipid lower therapy ( Livalo 4mg ) hyperlipidemic patient impair fast glucose ( IFG ) . H0 : µT-µC ≥ 0.4 v H1 : µT-µC &lt; 0.4 µT = change HbA1c test drug ( Pitavastatin 4 MG ) µC = change HbA1c control drug ( Pitavastatin 2 MG )</brief_summary>
	<brief_title>Evaluate Safety Efficacy Pitavastatin Patients With IFG Hyperlipidemia</brief_title>
	<detailed_description>Investigational Product Test group : Pitavastatin calcium ( LIVALO ) 4mg tab Control group : Pitavastatin calcium ( LIVALO ) 2mg tab Study Site : Multi-centers Korea Period : For 24months IRB approval site ( Including 12months subject enrollment period ) Efficacy End point A . Primary end point The change HbA1c take LIVALO B . Secondary end point 1 . Incidence diabetes within 1year registration ( base ; FPG ≥126mg/dL need take diabetes medication ) 2 . Incidence major cardiovascular ( TLR-MACE ) event within 1 year registration 3 . Incidence total cardiovascular ( TVR-MACE ) event within 1 year registration 4 . The change lipid composition ( T-chol , TG , LDL-C , HDL-C , ApoA1/ApoB ) 5 . The change hs-CRP 6 . The change Adiponectin 7 . The change blood glucose Insulin level FPG ( Fasting Plasma Glucose ) Fasting Serum Insulin HOMA IR [ fast insulin ( µIU/mL ) X fast glucose ( mg/dL ) ] /405 HOMA β [ 360 X fast insulin ( µIU/mL ) ] / [ fasting glucose ( mg/dL ) -63 ] Statistical Methods 1 . Efficacy A . Primary efficacy endpoint analysis Describe statistic basic HbA1c variation take LIVALO group . In order verify noninferiority test drug , check upper limit confidence interval one-sided 97.5 % le 0.4 % difference HbA1c variation control group test group , take LIVALO . B . Secondary efficacy endpoint analysis Continuous variable : Present mean , standard deviation , minimum , maximum value TC , TG , LDL-C , HDL-C , Fasting serum insulin , Fasting plasma glucose HOMA IR , HOMA β etc . visit group . In comparison intergroup , use two-sample t-test normal distribution use Wilcoxon rank sum test non-normal distribution . Also In comparison group , use pair t-test normal distribution use Wilcoxon sign rank test non-normal distribution . Discrete variable : The number percentage subject incidence DM cardiovascular event describe group ratio intergroup comparison use χ2-test Fisher 's exact test . 2 . Safety All AEs ADRs manifest described frequency percentage group use χ2-test Fisher 's exact test intergroup comparison rate AEs ADRs Laboratory test vital sign analyze descriptive statistic quantity group , comparison intergroup , use two-sample t-test normal distribution use Wilcoxon rank sum test non-normal distribution . Also , In comparison group , use pair t-test normal distribution use Wilcoxon sign rank test non-normal distribution . Clinical laboratory test analyze frequency percentage outside normal range subject , use χ2-test Fisher 's exact test intergroup .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>1 . Male Female patient 20 year old 70 year old less . 2 . Patient voluntarily sign write informed consent form 3 . Patient LDLC ≥ 100mg/dl diagnose hyperlipidemia 4 . Patient suspect Imparied Fasting Glucose ( IFG ) satisfy FPG level ≥ 100mg/dL &lt; 126mg/dL FPG measure twice . 1 . Patient familial hypercholesterolemia 2 . Patient diagnose Type1 , Type2 DM secondary DM ( diabetes mellitus ) screen visit ( Diagnostic criterion DM : HbA1c≥ 6.5 % ) 3 . Patient receive antidiabetic within 6weeks screen visit 4 . Patient take insulin continuously need future 5 . Patient history gastrectomy 6 . Patient suspect diagnosed malignant tumor within last 10 year 7 . Patient serious pancreatic disease endocrine disorder 8 . Patient currently take Cyclosporine 9 . Patient medical history hypersensitivity Pitavastatin calcium 10 . Patient suspect renal failure ( serum creatinine ≥2.0 mg/dL ) 11 . Patient suspect liver dysfunction ( 2.5 time upper limit normal AST ALT ) 12 . Patient 3 time upper limit normal CPK 13 . Patient breastfeeding , pregnant planning pregnancy 14 . Patient deem inappropriate subject opinion Principal Investigator Investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Livalo , pitavastatin , hyperlipidemia , IFG</keyword>
</DOC>